Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 1;1(3):213-228.
doi: 10.1198/sbr.2009.0014.

Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations

Richard F Potthoff  1 , Stephen L George
Affiliations

Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations

Richard F Potthoff et al. Stat Biopharm Res. .

Abstract

Phase I clinical trials are often subject to severe limitations. The most important one is that they typically allow only for binary response-toxic (1) or nontoxic (0)-rather than a range of responses from 0 to 1. They also may not allow a new patient to be treated until results for all previous patients are available. They may assign patients to doses in groups of two or more, rather than individually. They may require the selected dose to be one of a few prespecified doses. The flexible method proposed here addresses these four limitations. It adopts a quasi-Bayesian approach incorporating a logistic dose-response model with two parameters for the mean response. The response at any dose follows a beta distribution, which entails a third parameter. The choice of dose for a patient is based on a utility function that reflects the latest estimates of toxicity and of the variance of the estimate of the maximum tolerated dose (MTD). Simulations show that the method works well, and that a nonbinary toxicity measure leads to a far more accurate MTD estimate than does a binary one.

PubMed Disclaimer

References

    1. Bekele BN, Thall PF. Dose-Finding Based on Multiple Ordinal Toxicities in Phase I Oncology Trials. In: Chevret S, editor. Statistical Methods for Dose-Finding Experiments. Chichester, UK: Wiley; 2006. pp. 243–258.
    1. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. 2003. [ (accessed June 25, 2006)]. Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003 ( http://ctep.cancer.gov/forms/CTCAEv3.pdf), Publish Date: December 12, 2003.
    1. Cheung YK, Chappell R. Sequential Designs for Phase I Clinical Trials With Late-Onset Toxicities. Biometrics. 2000;56:1177–1182. - PubMed
    1. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PWT, Charnsangavej C, Delclos ME, O’Reilly M, Lee JE, Wolff RA. Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer. Journal of Clinical Oncology. 2006;24:1145–1151. - PubMed
    1. DeGroot MH. Optimal Statistical Decisions. New York: McGraw-Hill; 1970.

LinkOut - more resources